Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Beta3-Integrin Protein Possible Key to Block Tumor Growth

By BiotechDaily International staff writers
Posted on 15 Jan 2014
Print article
Image: Graphic of Cytoplasmic domain of the integrin beta-3 (Photo courtesy of Wikipedia Commons).
Image: Graphic of Cytoplasmic domain of the integrin beta-3 (Photo courtesy of Wikipedia Commons).
A protein that has been at the forefront of cancer drug development for the last 20 years should not be given up on according to new findings by British investigators.

The most advanced version of αvβ3-integrin antagonists was unsuccessful in clinical trials to treat aggressive forms of brain cancer. However, research published January 3, 2014, in the American Heart Association’s journal Circulation Research revealed that targeting the specific protein could still be key to blocking tumor growth. Most significantly, the drugs targeting the protein cause minimal side effects compared to other drugs, which can cause high blood pressure and bleeding in the gut.

Tumors must recruit their own blood supply to grow beyond a very small size. The researchers examined the cells that line blood vessels (endothelial cells) in mice, and specifically the role of a widely expressed protein called beta3-integrin.

Dr. Stephen Robinson, from the University of East Anglia’s (UEA; Norwich, UK) School of Biological Sciences, said, “This protein has been the focus of drug design over the last two decades because its expression is vastly increased in endothelial cells during blood vessel recruitment. The most advanced of these drugs, however, has recently failed a phase III clinical trial to treat an aggressive form of brain cancer. In line with other clinical work, patients respond to treatment for a short while but then their cancers escape the treatment. This research helps to explain why these very promising drugs aren’t meeting with the success that was anticipated and it suggests a way forward—how to make them work better.”

The study authors additionally reported that they revealed how tumors continue to grow in spite of treatment that should suppress blood vessel recruitment. In this study, they modulated how they are recruiting their blood vessels by using a different pathway from the one that is being targeted. They have identified some molecular alterations in endothelial cells that occur with long-term suppression of beta3-integrin that might help the cells evade the beta3-integrin blockade.

Dr. Robinson continued, “Our research also shows that timing is critical when targeting the protein beta3-integrin. Importantly, these findings have reestablished the expression of beta3-integrin as a valid clinical target when treating cancer. Efforts must now be refocused to either develop new drugs to target beta3-integrin, or figure out how to more effectively use the drugs that already exist.”

Related Links:

University of East Anglia



Print article

Channels

Genomics/Proteomics

view channel
Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).

Statins May Help Block Transmission of Lyme Disease

A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease. Lyme disease... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.